HCV infection on‐treatment viral kinetics: Do they still have a role?
Jordan J. Feld – 26 April 2012 – Watch the interview with the authors
Management of adverse events during the treatment of chronic hepatitis C infection
Douglas L. Nguyen, Timothy R. Morgan – 26 April 2012 – Watch the interview with the authors
Is there still a role for liver biopsy in managing hepatitis C virus infections?
Syed‐Mohammed R. Jafri, Stuart C. Gordon – 26 April 2012 – Watch the interview with the authors
Managing drug‐drug interactions with boceprevir and telaprevir
Amol S. Rangnekar, Robert J. Fontana – 26 April 2012 – Watch the interview with the authors
Alpha‐fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis
Edoardo G. Giannini, Simona Marenco, Giacomo Borgonovo, Vincenzo Savarino, Fabio Farinati, Paolo Del Poggio, Gian Ludovico Rapaccini, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Maria Chiaramonte, Franco Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group – 26 April 2012 – Alpha‐fetoprotein is a tumor marker that has been used for surveillance and diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. The prognostic capability of this marker in patients with HCC has not been clearly defined.
Bile acids in nonalcoholic steatohepatitis: Inserting nuclear receptors into the circle
Chiara Gabbi, Jan‐Åke Gustafsson – 26 April 2012
Issues in selecting HCV‐infected candidates for anti‐viral treatment
Anna S. Lok – 26 April 2012 – Watch the interview with the authors
Importance of patient education and monitoring among HCV‐infected patients selected for anti‐viral treatment
Corinne Wentworth‐Kotara, P.A‐C. – 26 April 2012 – Watch the interview with the authors
Treatment options for anti‐HCV treatment‐experienced patients
Peter Ferenci – 26 April 2012 – Watch the interview with the authors
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
George N. Ioannou, Christopher L. Bryson, Noel S. Weiss, Richard Miller, John D. Scott, Edward J. Boyko – 24 April 2012 – Cirrhosis is a leading cause of death among patients infected with human immunodeficiency virus (HIV). We sought to determine risk factors for and time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (HCC) among patients diagnosed with HIV who received care in the Veterans Affairs (VA) health care system nationally between 1996 and 2009 (n = 24,040 in 2009).